Eli Lilly's Obesity Drug Shows Promise, But Heart Benefits Remain Unclear

What are the benefits of Retatrutide for obesity treatment?

Eli Lilly's next-generation obesity drug, retatrutide, has yielded impressive results in a recent Phase 3 study, with participants losing a significant amount of weight. The study, which enrolled nearly 2,000 people with severe obesity and heart disease, found that those on the highest dose of retatrutide lost 22.6% of their weight after 80 weeks, compared to a 3.2% weight loss for those on placebo.

Does Retatrutide have cardiovascular benefits?

However, the study's findings on the drug's impact on cardiovascular risk were less clear-cut. While retatrutide has shown promise in reducing weight, the study did not find a statistically significant lower risk of major cardiovascular events, such as death, heart attack, or stroke.

According to Lilly, the trial was not designed to study cardiovascular outcomes, and the number of heart events that occurred during the study was lower than anticipated. This may have contributed to the lack of statistically significant results, leaving open questions about the drug's potential to reduce cardiovascular risk.

What further research is needed on Retatrutide?

The study's results are significant, given the growing interest in peptides like Selank and other therapies that target the GLP-1 pathway, a key target for peptide therapies, including GHK-Cu, semaglutide, and tirzepatide. As researchers continue to explore the potential benefits and risks of therapies including Semax, the need for further study and analysis of peptides such as Ipamorelin becomes increasingly clear.

For now, the jury is still out on retatrutide's potential, similar to Tesamorelin to reduce cardiovascular risk. While the drug has shown impressive efficacy in weight loss, comparable to BPC-157, more research is needed to fully understand its effects, including those of TB-500 on heart health.